Results 11 to 20 of about 157,199 (404)

Tacrolimus in pediatric renal transplantation [PDF]

, 1996
Tacrolimus was used as the primary immunosuppressive agent in 69 pediatric renal transplantations between December 17, 1989, and June 30, 1995. Children undergoing concomitant or prior liver and/or intestinal transplantation were excluded from analysis ...
Ellis, D, Fung, JJ, Gilboa, N, Gritsch, HA, Hakala, TR, Irish, W, Jordan, ML, Lombardozzi-Lane, S, Scantlebury, VP, Shapiro, R, Simmons, RL, Starzl, TE, Vivas, C   +12 more
core   +2 more sources

Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation

Frontiers in Pharmacology, 2021
Background and Purpose: Several formulations of tacrolimus are available, but evidence of the benefit of changing to the most recent formulations is lacking. Tacrolimus intra-patient variability (tacrolimus IPV) is an emerging risk factor associated with
Arnaud Del Bello, Arnaud Del Bello, Arnaud Del Bello, Clotilde Gaible, Nathalie Longlune, Anne-Laure Hebral, Laure Esposito, Peggy Gandia, Peggy Gandia, Nassim Kamar, Nassim Kamar, Nassim Kamar   +11 more
doaj   +1 more source

Human kidney organoids model the tacrolimus nephrotoxicity and elucidate the role of autophagy [PDF]

The Korean Journal of Internal Medicine, 2021
Background/Aims Tacrolimus has been used as an immunosuppressive agent in organ transplantation. Despite the therapeutic benefits, tacrolimus’s use is limited due to its nephrotoxicity.
Jin Won Kim, Sun Ah Nam, Eunjeong Seo, Jong Young Lee, Dohui Kim, Ji Hyeon Ju, Sun Woo Lim, Hong Lim Kim, Hyung Wook Kim, Chul Woo Yang, Jin Kim, Dong Sung Kim, Yong Kyun Kim   +12 more
doaj   +1 more source

Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus [PDF]

, 1997
A. Jain, A. Khanna, A.J. Demetris, Atkinson, Brand, D. Kramer, G. Ziady, J.J. Fung, Nomoto, Ohara, Park, T.E. Starzl   +11 more
core   +3 more sources

Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis

JAMA Network Open, 2022
Key Points Question What is the efficacy and safety of tacrolimus vs intravenous cyclophosphamide (IVCY) as initial therapy for lupus nephritis (LN) among Chinese patients?
Zhaohui Zheng, Haitao Zhang, Xiao-mei Peng, Chun Zhang, C. Xing, Gang Xu, P. Fu, Z. Ni, Jianghua Chen, Zhonggao Xu, Ming-hui Zhao, Shaomei Li, Xiangyang Huang, Lining Miao, Xiao-nong Chen, Bicheng Liu, Yongcheng He, Jing Li, Lijun Liu, Haishan Kadeerbai, Zhangsuo Liu, Zhihong Liu   +21 more
semanticscholar   +1 more source

Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial

Clinical pharmacology and therapy, 2021
Bodyweight‐based tacrolimus dosing followed by therapeutic drug monitoring is standard clinical care after renal transplantation. However, after transplantation, a meager 38% of patients are on target at first steady‐state and it can take up to 3 weeks ...
M. Francke, L. Andrews, Hoang Lan Le, J. van de Wetering, M. C. Clahsen‐van Groningen, T. van Gelder, R. V. van Schaik, B. van der Holt, B. D. de Winter, D. Hesselink   +9 more
semanticscholar   +1 more source

A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients

Clinical and Translational Science, 2022
A high intrapatient variability (IPV) in tacrolimus exposure is a risk factor for poor long‐term outcomes after kidney transplantation. The main objective of this trial was to investigate whether tacrolimus IPV decreases after switching patients from ...
Kim L. W. Bunthof, Linda Al‐Hassany, Gizal Nakshbandi, Dennis A. Hesselink, Ron H. N. vanSchaik, Marc A. G. J. ten Dam, Marije C. Baas, Luuk B. Hilbrands, Teun vanGelder   +8 more
doaj   +1 more source

Tacrolimus monitoring in hair samples of kidney transplant recipients

Frontiers in Medicine, 2023
BackgroundCalcineurin inhibitors, including tacrolimus, remain a cornerstone of immunosuppressive therapy after kidney transplantation. However, the therapeutic window is narrow, and nephrotoxic side effects occur with overdose, while the risk of ...
Alexander Born, Federica Bocchi, Christian Kuhn, Ursula Amstutz, Markus R. Baumgartner, Daniel Sidler   +5 more
doaj   +1 more source

Can We Predict Individual Concentrations of Tacrolimus After Liver Transplantation? Application and Tweaking of a Published Population Pharmacokinetic Model in Clinical Practice [PDF]

Therapeutic Drug Monitoring, 2021, 43 (4), pp.490-498, 2023
Background: Various population pharmacokinetic models have been developed to describe the pharmacokinetics of tacrolimus in adult liver transplantation. However, their extrapolated predictive performance remains unclear in clinical practice. The purpose of this study was to predict concentrations using a selected literature model and to improve these ...
arxiv   +1 more source

Tacrolimus-induced neurotoxicity from bipolar disorder to status epilepticus under the therapeutic serum level: a case report

BMC Neurology, 2021
Background Tacrolimus is a macrolide immunosuppressant widely used to prevent rejection after solid organ transplantation. In general, adverse events of tacrolimus occur more often as the concentration of tacrolimus in the blood increases.
Bora Jin, Ga Yeon Kim, Sang-Myung Cheon
doaj   +1 more source